Beyond Achondroplasia

Growing together with Clara

BioMarin at the Wells Fargo 9th Annual Healthcare Conference

| 2 Comments

Dan Oppenheimer, Group Vice President, Development & Portfolio Strategy – BioMarin Pharmaceutical Inc, presented today at the Wells Fargo research conferences the actual state of art of BioMarin´s drugs under evaluation, including BMN-111.

Has said, BioMarin predicts to have results from the BMN-111 phase 2 on the second quarter of 2015.

BMN-111 is expected to have it´s final dosis between cohort 1) 2.5 microgram/kg and cohort 2) 7.5 microgram/kg.

To listen to the webcast here, (starting at minute 16).

 

Still a long road to travel.

 

2 Comments

  1. I hardly leave a response, however i did some searching and
    wound up here BioMarin at the Wells Fargo 9th Annual Heallthcare Conference | Beyond achondroplasia.
    And I actually ddo have 2 questions for you if it’s allright.

    Is iit only me or does it seem like a feew of these remarks come across lile
    left by brain dead visitors? 😛 And, iif you are writing at other
    social sites, I would like to follow everything new you have too post.
    Could you make a list of every onee off all your shared sites like
    your Facebook page, twitter feed, or linkedin profile?

Leave a Reply

Required fields are marked *.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

Translate »